- Home
- SUPV vs CERT Comparison
SUPV vs CERT Comparison
Compare SUPV & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | CERT |
|---|---|---|
| Founded | 1887 | 2008 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 808.9M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SUPV | CERT |
|---|---|---|
| Price | $9.79 | $7.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $13.00 | $11.67 |
| AVG Volume (30 Days) | 819.0K | ★ 5.0M |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $86.20 | $4.18 |
| Revenue Next Year | $25.12 | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $4.54 | $4.45 |
| 52 Week High | $13.55 | $13.88 |
Technical Indicators
Market Signals| Indicator | SUPV | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 73.69 |
| Support Level | $9.27 | $5.93 |
| Resistance Level | $10.12 | $7.52 |
| Average True Range (ATR) | 0.64 | 0.44 |
| MACD | -0.11 | 0.18 |
| Stochastic Oscillator | 25.54 | 89.53 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.